Department of Biotechnology, Faculty of Science, Lincoln University College, Selangor, Malaysia
Copyright ©2020, Korea Centers for Disease Control and Prevention
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Has acute respiratory infection (either with difficulty in breathing, sore throat, or dry cough) with or without fever AND
Had a history of travel to or resided in a foreign country within 14 days before onset of disease OR
Had close contact with an infected person in the last 14 days before the onset of symptoms
Attended a gathering or event linked to a COVID-19 outbreak
Stage 1. asymptomatic,
Stage 2. symptomatic and no pneumonia,
Stage 3. symptomatic and pneumonia,
Stage 4. symptomatic, pneumonia and supplemental oxygen required,
Stage 5. critically ill with multiorgan failure
Stage 1. No treatment required
Stage 2. Hydroxychloroquine only
Stage 3/4. Hydroxychloroquine combined treatment with Lopinavir/Ritonavir
Stage 5. Hydroxychloroquine combined treatment with Lopinavir/Ritonavir, Ribavarin or Interferon Beta [21].
✓ Wash hands frequently with soap and water or an alcohol-based hand sanitizer
✓ Wear face mask and gloves
✓ Maintain physical distancing of 1metre
✓ Mass gatherings have been stopped
✓ Cover mouth and nose with a disposable tissue or flexed elbow when coughing or sneezing
✓ Avoid touching eyes, mouth, or nose
✓ Avoid handshaking
✓ Stay at home if immunocompromised or has comorbidities
✓ Avoid traveling to COVID-19 affected areas or countries
✓ Self-isolate at home for 14 days upon return from overseas if symptomatic
✓ Screen for COVID-19 after a person returns from a foreign country
✓ Avoid spreading false information regarding COVID-19
✓ People were prohibited from attending mass gatherings such as religious, sports, social, and cultural events. All places of worship and businesses were closed temporarily. However, people could buy essential goods at markets, supermarkets, grocery shops and convenience stores.
✓ People were required to undergo health screening for the detection of COVID-19 and self-isolate after returning from overseas.
✓ Foreign tourists and visitors were forbidden entry to Malaysia.
✓ Kindergartens, government, and private schools including daily schools, boarding schools, international schools, tahfiz centers, other primary, secondary and pre-university institutions were all closed.
✓ Public and higher education institutions and skill training institutes nationwide were closed.
✓ Government and private premises were closed except for essential services (water, electricity, energy, telecommunications, postal, transportation, irrigation, oil, gas, fuel, lubricants, broadcasting, finance, banking, health, pharmacy, fire, prison, port, airport, safety, defense, cleaning, retail and food supply).
SARS-CoV | MERS-SARS | SARS-CoV-2 | |
---|---|---|---|
Coronaviriniae Genera | b-coronavirus, lineage B | b-coronavirus, lineage C | b-coronavirus, lineage B |
Virus type | RNA virus | RNA virus | RNA virus |
Total length of DNA sequence | 29,751 | 30,111 | 29,903 |
Discovery (y) | 2003 | 2012 | 2019 |
Origin | Guangdong province, China | Arabian Peninsula | Hubei province, China |
Total No. of cases worldwide (WHO report) | > 8,000 | 2,494 | 2,230,439 (Till 17th April 2020) |
Total No. of affected countries (WHO report) | 26 | 27 | 210 |
Total number of death cases (WHO report) | 916 | 858 | 150,837 (As of 17th April 2020) |
Mortality | >10% | 34.4% | 2.10% |
Transmission mode | -Droplets (coughing and sneezing) -Close contact with an infected person |
-Droplets (coughing and sneezing) -Close contact with an infected person |
-Droplets (coughing and sneezing) -Close contact with an infected person or even asymptomatic ones |
Transmission medium | Animal to human Human to human |
Animal to human Human to human |
Animal to human Human to human |
Transmission region | Globally | Regionally | Globally |
Cellular receptor | Angiotensin-Converting Enzyme 2 (ACE 2) | Dipeptidyl peptidase 4 (DDP4) | Angiotensin-Converting Enzyme 2 (ACE2) |
Reservoir | Palm Civets and Bats | Bats and Camels | Bats |
Receptor binding domain (RBD) | C-domain | C-domain | C-domain |
IFN-γ inhibitor | Yes | Yes | Unknown |
Viral replication efficiency | High | Higher | Higher |
Pathogenicity | Higher | High | High |
Clinical symptoms (WHO report) | Fever, malaise, myalgia, headache, diarrhea, and shivering (rigors) | Fever, cough, and shortness of breath | Fever, tiredness, and dry cough |
Prevention | -Hand wash -Wear mask and gloves -Physical distancing |
-Hand wash -Wear mask and glove -Physical distancing |
-Hand wash -Wear mask and gloves -Physical distancing |
Treatment | Glucocorticoid and interferon | No vaccine or specific treatment | No specific antiviral treatment |
Drugs | Mechanism |
---|---|
Remdesivir | Blocks viral RNA-dependent RNA polymerase activity (inhibits RNA replication from the RNA template) |
Chloroquine and hydroxychloroquine | Inhibits endocytosis by increasing the acidity in endosomes and prevents the entry of virus into the host cell. |
Lopinavir and ritonavir | Inhibits RNA translation process |
Lopinavir and ritonavir plus interferon-beta | Inhibits viral replication |
Camostat mesylate | Inhibits enzymatic activity of type II transmembrane serine protease (TMPRSS2) which is important for infectious viral entry into the host cell |
Darunavir | Blocks viral replication |
BCR-ABL kinase inhibitor imatinib | Inhibits fusion of virions with the endosomal membrane |
Arbidol | Inhibits membrane fusion of the viral envelope |
Ribavarin | Inhibits viral RNA synthesis and mRNA capping |
Ribavirin plus interferon-beta | Shuts down viral replication |
Umifenovir | Inhibits fusion of virions with the endosomal membrane |
Oseltamivir | Inhibits RNA translation process |
Interferon-beta | Triggers the activation of innate antiviral immunity |
Favipiravir | Blocks viral RNA-dependent RNA polymerase activity (inhibits RNA replication from RNA template) |
Monoclonal antibodies | Inhibits viral infection via binding to the virus |
MERS-CoV = Middle East respiratory syndrome coronavirus; SARS-CoV = severe acute respiratory syndrome coronavirus; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; WHO = World Health Organization.
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.